Irbesartan Zydus

Irbesartan, the active ingredient in Irbesartan Zydus, is an Angiotensin II receptor blocker (ARB) presented as an oral tablet for oral use. It is used to manage high blood pressure and related cardiovascular conditions in adult patients.

GNH USA supplies Irbesartan Zydus as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Irbesartan Zydus is indicated for conditions that involve the renin‑angiotensin system and related cardiovascular disease. - Hypertension: lowers systolic and diastolic blood pressure, reducing cardiovascular risk. - Diabetic nephropathy: slows progression of kidney damage in patients with type 2 diabetes. - Heart failure: improves symptoms and reduces hospitalisation in patients with reduced ejection fraction.

Irbesartan may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Dizziness - Headache - Fatigue - Nasal congestion

Serious or Rare Side Effects: - Angioedema (swelling of face, lips, tongue) - Severe hyperkalemia (elevated blood potassium) - Acute renal failure or significant rise in serum creatinine

When prescribing Irbesartan, clinicians should consider several safety measures. - Renal function monitoring: assess serum creatinine and eGFR before and during therapy. - Electrolyte monitoring: check potassium levels regularly, especially in patients with renal impairment or on potassium‑sparing diuretics. - Pregnancy contraindication: avoid use in pregnancy due to risk of fetal toxicity. - Drug interactions: review concomitant medications that affect potassium or renal function. - Store at ambient temperature: keep below 25 °C, protect from moisture and light in the original packaging.

Irbesartan can interact with several drug classes, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Potassium‑sparing diuretics (e.g., spironolactone): risk of severe hyperkalemia. - ACE inhibitors or other ARBs: additive effect on blood pressure and potassium. - Aliskiren in diabetic patients: increased renal risk. - High‑dose NSAIDs: may reduce antihypertensive effect and impair renal function.

Moderate Interactions (Monitor Closely): - Lithium: may increase serum lithium levels. - Cyclosporine or tacrolimus: may increase serum creatinine. - Thiazide diuretics: may enhance hypotensive effect.